Bradley Canino
Stock Analyst at Stifel
(1.57)
# 3,437
Out of 5,163 analysts
82
Total ratings
32.88%
Success rate
-4.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $46 → $38 | $13.58 | +179.82% | 4 | Dec 2, 2025 | |
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $23.50 | +87.23% | 7 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.12 | +607.55% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.98 | -24.24% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $13.49 | +40.85% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $10.36 | +122.01% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $12.18 | +318.72% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $8.65 | +119.65% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $114.22 | -63.23% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $16.12 | +148.14% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $97.93 | +37.85% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $11.90 | +68.07% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.54 | +549.35% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.71 | +269.00% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.72 | +414.71% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $79.03 | -30.41% | 4 | Feb 23, 2024 |
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $46 → $38
Current: $13.58
Upside: +179.82%
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $23.50
Upside: +87.23%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.12
Upside: +607.55%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.98
Upside: -24.24%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $13.49
Upside: +40.85%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $10.36
Upside: +122.01%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $12.18
Upside: +318.72%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $8.65
Upside: +119.65%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $114.22
Upside: -63.23%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $16.12
Upside: +148.14%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $97.93
Upside: +37.85%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $11.90
Upside: +68.07%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.54
Upside: +549.35%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.71
Upside: +269.00%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.72
Upside: +414.71%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $79.03
Upside: -30.41%